Your AI-Trained Oncology Knowledge Connection!

Expert Perspectives in Testing and Targeted Therapy: Managing Patients with EGFR Exon20+ NSCLC : Episode 7

Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy

July 31, 2023

By Joshua K. Sabari, MD
Misako Nagasaka, MD

Video

A brief review of novel EGFR TKIs that may have stronger CNS penetration in patients with non–small cell lung cancer and brain metastases.

EP: 1.Paradigm of NGS Testing in Patients With Advanced NSCLC

EP: 2.Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer

EP: 3.First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC

EP: 4.Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC

EP: 5.EGFR Exon20+ NSCLC: Trial Data With Mobocertinib

EP: 6.Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC

EP: 7.Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy

EP: 8.Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care

EP: 9.Amivantamab vs Mobocertinib in Exon 20 NSCLC

EP: 10.Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.

2 experts in this video

2 experts in this video

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.